Working… Menu

SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02332850
Recruitment Status : Unknown
Verified September 2017 by University of California, San Francisco.
Recruitment status was:  Recruiting
First Posted : January 7, 2015
Last Update Posted : September 18, 2017
Information provided by (Responsible Party):
University of California, San Francisco

Brief Summary:

This study will be conducted as a standard Phase 1b, open-label, multi-center study of patients with relapsed and/or refractory Myeloma who have received at least two prior therapeutic treatments or regimens. Throughout the Phase I portion of this study, a standard 3+3 dose escalation design will be utilized. Two dosing cohorts will evaluate escalating doses SAR650984 (5mg/kg and 10 mg/kg Day 1 and 15 of each 28-day cycle) with standard dose Carfilzomib (20-27 mg/mg2). Once a safe dose is established, an expansion cohort will further evaluate safety and begin to assess activity of this combination (SAR650984 (5mg/kg or 10 mg/kg Day 1 and 15 of each 28-day cycle) with standard dose Carfilzomib).

During the dose escalation portion of the study, the DLT period will be the first cycle (28 days) or from Day 1 through Day 28 of initial study treatment.

Expansion Phase Cohort An expansion cohort will begin once the MTD of SAR650984 plus standard dose Carfilzomib is established. The Expansion Cohort will enroll 18 patients for additional safety and preliminary efficacy data of SAR650984 plus Carfilzomib at the MTD.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: SAR650984 Drug: Carfilzomib Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 42 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination With Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma
Study Start Date : December 2014
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma
Drug Information available for: Carfilzomib

Arm Intervention/treatment
Experimental: Treatment
SAR650984: 5 mg/kg or 10 mg/kg Day 1 and 15 of each 28-day cycle (escalating cohorts) Carfilzomib: standard dose (20-27 mg/m2)
Drug: SAR650984
Drug: Carfilzomib

Primary Outcome Measures :
  1. Adverse Events [ Time Frame: Approximately up to 2 years ]
  2. Maximum Tolerated Dose [ Time Frame: Approximately up to 2 years ]

Secondary Outcome Measures :
  1. Immunogenicity of SAR650984 [ Time Frame: Approximately up to 2 years ]
    Elisa assay for serum anibodies that bind to SAR650984

  2. Overall response rate [ Time Frame: Approximately up to 2 years ]
  3. Clinical benefit response [ Time Frame: Approximately up to 2 years ]
    measured by Complete Response + Very Good Partial Response + Partial Response + Minimal Remission/Response

  4. Overall survival (OS) [ Time Frame: 1 year ]
  5. Progression Free Survival (PFS) [ Time Frame: Approximately up to 2 years ]
  6. Time To Progression (TTP) [ Time Frame: Approximately up to 2 years ]
  7. Duration of Response (DOR) [ Time Frame: Approximately up to 2 years ]
  8. CD38 receptor density levels [ Time Frame: Baseline ]
  9. Receptor density levels [ Time Frame: Within 60 days of last dose of study drug ]
  10. Receptor occupancy [ Time Frame: Within 60 days of last dose of study drug ]
    Analysis of the amount of SAR650984 bound to the CD38 receptor divided by CD38 receptor density by immunohistochemistry and flow cytometry

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males or females, age 18 years or older.
  • Diagnosis of MM and documentation of treatment with an IMiD® and proteasome inhibitor. Must have had 2 prior regimens/lines of therapy but there is no maximum number of prior regimens and prior autologous bone marrow transplant is acceptable if > 12 weeks from transplantation. A line of therapy is defined as a course of therapy that is not interrupted by progressive disease. For example, induction therapy, autologous stem cell transplantation, and maintenance therapy without intervening progressive disease is one line of therapy.
  • Confirmed evidence of relapse/disease progression from immediately prior MM therapy or refractory to the immediately prior treatment. Refractory disease is defined as those who are non-responsive (< minimal response) on active therapy or experience disease progression within 60 days after the discontinuation of therapy. Relapsed disease is defined as achievement of at least a minimal response followed by disease progression on therapy or within 60 days of discontinuing active therapy.
  • Patients may have received prior Carfilzomib (sensitive, relapsed and refractory all eligible) but must be > 4 weeks from last dosing of Carfilzomib. In the expansion cohort, at least 10 patients will be required to be refractory to Carfilzomib (refractory defined as having evidence of disease progression while receiving Carfilzomib or within 60 days of stopping Carfilzomib therapy).
  • Patients must have measurable disease defined as at least one of the following:
  • Serum M-protein ≥0.5 g/dl (≥5 g/l)
  • Urine M-protein ≥200 mg/24 h
  • Serum FLC assay: Involved FLC level ≥10 mg/dl (≥100 mg/l) and an abnormal serum free light chain ratio (<0.26 or >1.65)
  • Quantitative immunoglobulin > 500mg/dL, only for IgA and IgD myeloma when the protein electrophoresis under-represents disease burden.
  • Biopsy proven plasmacytoma (should be measured within 28 days prior to initial investigational agent dosing).
  • Subject has an ECOG ≤ 2 performance status OR Karnofsky ≥ 60% performance status.
  • Females of childbearing potential (FCBP) - A female of childbearing potential is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months may be included if the patient is not pregnant by a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. Females must agree to avoid pregnancy during the study and must agree to use a medically acceptable method of birth control as determined by the study doctor while participating in the study and for at least 12 weeks after the last dose of study medication.
  • Voluntary written informed consent before performance of any study-related procedure not part of routine medical care with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
  • Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local subject privacy regulations).

Inclusion Clinical Laboratories Criteria

  • The following laboratory results must be met within 7 days of study drug (treatment) administration
  • Absolute neutrophil count (ANC) > 1,000 cells/dL (1.0 x 10e9/L) (Growth factor cannot be used within the previous 7 days)
  • Hemoglobin ≥ 8.0 g/dl (without transfusion within the previous 7 days).
  • Platelet count > 50,000 cells/dL (50 x 10e9/L)
  • Creatinine clearance ≥ 30 mL/min (Cockcroft-Gault equation)
  • Serum SGOT/AST or SGPT/ALT < 2.5 x upper limit of normal (ULN)
  • Total bilirubin ≤ 1.5 x ULN
  • Serum calcium (corrected for albumin) level at or below the ULN range (treatment of hypercalcemia is allowed and subject may enroll if hypercalcemia returns to normal with standard treatment) prior to study therapy initiation.
  • Left ventricular ejection fraction; LVEF ≥40% (By echocardiogram or MUGA testing).

Exclusion Criteria:

  • Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, low-risk prostate cancer after curative therapy or complete resection of other advanced malignancy with the expectation that the patient has received curative therapy.
  • Patient has received other investigational drugs with 21 days before enrollment (or must be > than four half-lives of the experimental agent). No prior SAR650984 anti-CD38 antibody therapy allowed.
  • History of significant cardiovascular disease unless the disease is well-controlled or history of myocardial infarction in the past 6 months. Significant cardiac diseases includes second/third degree heart block; significant conduction abnormalities, significant ischemic heart disease; QTc interval > 480 msec at baseline (using Bazett's formula and read by local cardiologist); poorly controlled hypertension; congestive heart failure of New York Heart Association (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea) and inability to tolerate intravenous hydration necessary for study therapy administration.
  • Prior peripheral stem cell transplant within 12 weeks of the first dose of study treatment
  • Daily requirement for corticosteroids (>10 mg prednisone QD or equivalent)
  • Patients with evidence of significant mucosal or internal bleeding
  • Prior radiation therapy or chemotherapy within 2 weeks or major surgical procedure within 4 weeks of the first dose of study treatment.
  • Known active infection requiring parenteral or oral anti-infective treatment, once a patient has completed antibiotics and symptoms of infection have resolved to <Grade 2, they are then considered eligible from an infection standpoint.
  • Serious psychiatric illness, active alcoholism, or drug addiction that may hinder or confuse follow-up evaluation.
  • Any medical conditions that, in the Investigator's opinion, would impose excessive risk to the patient. Examples of such conditions include any pre-existing kidney disease (acute or chronic, unless renal insufficiency is felt to be secondary to MM), hypertension, active seizure disorder or pulmonary diseases that would impose excessive risk to the patient.
  • Patient has hypersensitivity to any of the components of study therapy including required prophylactic medications.
  • Known HIV seropositivity or active hepatitis B or C viral infection
  • Neuropathy ≥Grade 3 or painful neuropathy ≥Grade 2 (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v4.03)
  • Gastro-intestinal abnormalities, including bowel obstruction, inability to take oral medication, requirement for intravenous (IV) alimentation, active peptic ulcer or prior surgical procedures or bowel resection affecting absorption.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02332850

Layout table for location contacts
Contact: Thomas Martin, MD 415-353-9365
Contact: Alyson Cockerill 415-353-4091

Layout table for location information
United States, California
UCSF, 400 Parnassus Ave Recruiting
San Francisco, California, United States, 94143
Contact: Paul Formaker    415-885-7871   
Sponsors and Collaborators
University of California, San Francisco

Layout table for additonal information
Responsible Party: University of California, San Francisco Identifier: NCT02332850     History of Changes
Other Study ID Numbers: 139511
First Posted: January 7, 2015    Key Record Dates
Last Update Posted: September 18, 2017
Last Verified: September 2017
Keywords provided by University of California, San Francisco:
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases